| Income Statement | 2025-09-30 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total non-operating income (expenses), net | 86,206 | -9,482 | -46,290 | |
| Income (loss) before income taxes | 141,137 | -6,339 | -65,390 | |
| Income tax expense | 23,864 | 833 | -13,479 | |
| Net (loss) income from continuing operations | - | -7,172 | -51,911 | |
| Net income (loss) | 117,273 | -7,172 | -51,911 | |
| Basic net income (loss) per share (in usd per share) | 5.99 | -0.39 | -2.88 | |
| Diluted net income (loss) per share (in usd per share) | 5.68 | -0.39 | -2.88 | |
| Shares used in basic per share calculation (in shares) | 19,578,000 | 18,419,000 | 18,028,000 | |
| Shares used in diluted per share calculation (in shares) | 20,629,000 | 18,419,000 | 18,028,000 | |
LIGAND PHARMACEUTICALS INC (LGND)
LIGAND PHARMACEUTICALS INC (LGND)